Localization of CDR2L and CDR2 in paraneoplastic cerebellar degeneration.


Journal

Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278

Informations de publication

Date de publication:
11 2020
Historique:
received: 26 06 2020
revised: 07 08 2020
accepted: 11 09 2020
pubmed: 4 10 2020
medline: 25 9 2021
entrez: 3 10 2020
Statut: ppublish

Résumé

Identify the subcellular location and potential binding partners of two cerebellar degeneration-related proteins, CDR2L and CDR2, associated with anti-Yo-mediated paraneoplastic cerebellar degeneration. Cancer cells, rat Purkinje neuron cultures, and human cerebellar sections were exposed to cerebrospinal fluid and serum from patients with paraneoplastic cerebellar degeneration with Yo antibodies and with several antibodies against CDR2L and CDR2. We used mass spectrometry-based proteomics, super-resolution microscopy, proximity ligation assay, and co-immunoprecipitation to verify the antibodies and to identify potential binding partners. We confirmed the CDR2L specificity of Yo antibodies by mass spectrometry-based proteomics and found that CDR2L localized to the cytoplasm and CDR2 to the nucleus. CDR2L co-localized with the 40S ribosomal protein S6, while CDR2 co-localized with the nuclear speckle proteins SON, eukaryotic initiation factor 4A-III, and serine/arginine-rich splicing factor 2. We showed that Yo antibodies specifically bind to CDR2L in Purkinje neurons of PCD patients where they potentially interfere with the function of the ribosomal machinery resulting in disrupted mRNA translation and/or protein synthesis. Our findings demonstrating that CDR2L interacts with ribosomal proteins and CDR2 with nuclear speckle proteins is an important step toward understanding PCD pathogenesis.

Identifiants

pubmed: 33009713
doi: 10.1002/acn3.51212
pmc: PMC7664253
doi:

Substances chimiques

Autoantibodies 0
Autoantigens 0
CDR2 protein, human 0
CDR2L antigen, human 0
Nerve Tissue Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2231-2242

Informations de copyright

© 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

Références

Cell. 2012 Nov 9;151(4):750-764
pubmed: 23084401
Genes Dev. 1999 Aug 15;13(16):2087-97
pubmed: 10465786
Exp Cell Res. 1998 Jun 15;241(2):363-72
pubmed: 9637778
Neurobiol Dis. 2004 Apr;15(3):529-33
pubmed: 15056460
J Neuropathol Exp Neurol. 2010 Oct;69(10):997-1007
pubmed: 20838245
J Neurol Neurosurg Psychiatry. 2004 Jun;75 Suppl 2:ii43-50
pubmed: 15146039
Acta Neurol Scand. 2009 Jul;120(1):64-7
pubmed: 19486326
PLoS One. 2013 Jun 18;8(6):e66002
pubmed: 23823982
Cancer Immunol Immunother. 2011 Feb;60(2):283-9
pubmed: 21080165
Eur J Neurol. 2006 Jul;13(7):682-90
pubmed: 16834698
Front Mol Neurosci. 2015 Dec 16;8:75
pubmed: 26733799
Nat Struct Mol Biol. 2008 Aug;15(8):819-26
pubmed: 18641664
Adv Neurobiol. 2018;20:283-301
pubmed: 29916024
Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3451-4
pubmed: 2014264
Mol Cell. 2011 Apr 22;42(2):185-98
pubmed: 21504830
Cancer Immunol Immunother. 2017 Nov;66(11):1463-1471
pubmed: 28710511
Mol Cell Proteomics. 2005 Dec;4(12):2010-21
pubmed: 16249172
J Cell Biol. 2018 Jan 2;217(1):51-63
pubmed: 29127110
Acta Neuropathol. 2014 Dec;128(6):835-52
pubmed: 25341622
Brain Commun. 2020 Aug 03;2(2):fcaa059
pubmed: 32954318
Trends Biochem Sci. 2006 Jun;31(6):342-8
pubmed: 16679021
J Neurosci. 1997 Feb 15;17(4):1406-15
pubmed: 9006982
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Arch Neurol. 1994 Jun;51(6):555-8
pubmed: 8198465
Biochem Biophys Res Commun. 1991 Jul 15;178(1):198-206
pubmed: 1712585
Acta Neuropathol. 2018 Apr;135(4):569-579
pubmed: 29299667
Neurology. 1988 Sep;38(9):1380-6
pubmed: 3045692
J Biol Chem. 2001 Aug 17;276(33):30914-22
pubmed: 11418588
N Engl J Med. 2003 Oct 16;349(16):1543-54
pubmed: 14561798
Nucleic Acids Res. 2017 Jan 4;45(D1):D362-D368
pubmed: 27924014
Mol Biol Cell. 2010 Feb 15;21(4):650-63
pubmed: 20053686
Nat Med. 1998 Nov;4(11):1321-4
pubmed: 9809559
Nat Struct Mol Biol. 2012 Jun 05;19(6):568-76
pubmed: 22664984
RNA. 2004 Feb;10(2):200-9
pubmed: 14730019
J Cell Sci. 2017 Dec 15;130(24):4180-4192
pubmed: 29133588
Anal Chem. 2003 Feb 1;75(3):663-70
pubmed: 12585499
Mol Cell Neurosci. 2002 Apr;19(4):477-84
pubmed: 11988016
Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10195-9
pubmed: 8816775
Neurology. 1992 Oct;42(10):1931-7
pubmed: 1407575
Ann Neurol. 2019 Aug;86(2):316-321
pubmed: 31148214
Front Mol Neurosci. 2017 Dec 21;10:419
pubmed: 29311811

Auteurs

Ida Herdlevaer (I)

Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Department of Neurology, Haukeland University Hospital, Bergen, Norway.

Torbjørn Kråkenes (T)

Department of Clinical Medicine, University of Bergen, Bergen, Norway.

Manja Schubert (M)

Department of Neurology, Haukeland University Hospital, Bergen, Norway.

Christian A Vedeler (CA)

Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Department of Neurology, Haukeland University Hospital, Bergen, Norway.
Departments of Neurology and Clinical Medicine, Neuro-SysMed - Centre of Excellence for Experimental Therapy in Neurology, Bergen, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH